Kirk Allan D, Mannon Roslyn B, Swanson S John, Hale Douglas A
Transplantation Branch, Department of Health and Human Services, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Center Drive, Bethesda, MD 20892, USA.
Transpl Int. 2005 Jan;18(1):2-14. doi: 10.1111/j.1432-2277.2004.00019.x.
Immunosuppression remains the cause of most morbidity following organ transplantation. However, its use is also responsible for the outstanding graft and patient survival rates commonplace in modern transplantation. Thus, the predominant challenge for transplant clinicians is to provide a level of immunosuppression that prevents graft rejection while preserving immunocompetence against environmental pathogens. This review will outline several strategies for minimizing or tailoring the use of immunosuppressive drugs. The arguments for various strategies will be based on clinical trial data rather than animal studies. A distinction will be made between conventional immunosuppressive drug reduction based on over-immunosuppression, and newer induction methods specifically designed to lessen the need for chronic immunosuppression. Based on the available data we suggest that most patients can be transplanted with less immunosuppression than is currently standard.
免疫抑制仍然是器官移植后大多数发病情况的原因。然而,其使用也是现代移植中普遍存在的出色移植物和患者存活率的原因。因此,移植临床医生面临的主要挑战是提供一定水平的免疫抑制,既能防止移植物排斥,又能保持对环境病原体的免疫能力。本综述将概述几种尽量减少或调整免疫抑制药物使用的策略。各种策略的依据将是临床试验数据而非动物研究。将区分基于过度免疫抑制的传统免疫抑制药物减量,以及专门设计以减少对慢性免疫抑制需求的新型诱导方法。根据现有数据,我们认为大多数患者移植时所需的免疫抑制比目前的标准要少。